Mouse Genome Informatics
hm
    Smarcal1tm1.1Cfbo/Smarcal1tm1.1Cfbo
either: B6.129-Smarcal1tm1.1Cfbo or (involves: 129 * C57BL/6)
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• all die within 6 hours of being housed at 39.5 degrees C, whereas only 20% of wild-type controls died in 10 h under the same conditions

immune system

homeostasis/metabolism
• in mice treated with 0.1 mg/kg/day alpha-amanitin
• mice treated with 0.1 mg/kg/day alpha-amanitin develop features similar to Schimke Type Immunoosseous Dysplasia (OMIM 242900)

growth/size/body
• display weight growth restriction when treated with 0.1 mg/kg/day alpha-amanitin
• display length growth restriction when treated with 0.1 mg/kg/day alpha-amanitin
• display length and weight growth restriction when treated with 0.1 mg/kg/day alpha-amanitin
• in the absence of treatment growth is similar to wild-type mice

skeleton
• distal femur plates are hypocellular in mice treated with 0.1 mg/kg/day alpha-amanitin
• chrondrocytes form less organized columns in mice treated with 0.1 mg/kg/day alpha-amanitin
• chrondrocytes form less organized columns in mice treated with 0.1 mg/kg/day alpha-amanitin
• disproportionately short spine in mice treated with 0.1 mg/kg/day alpha-amanitin

renal/urinary system
• in mice treated with 0.1 mg/kg/day alpha-amanitin

cellular
• when treated with 1 ug/ml alpha-amanitin MEFs proliferate more slowly compared to wild-type cells

hematopoietic system

Mouse Models of Human Disease
OMIM IDRef(s)
Immunoosseous Dysplasia, Schimke Type 242900 J:183899